Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis
Bahman Amani, Behnam Amani
Immunity, Inflammation and Disease, doi:10.1002/iid3.1262
Background and Aim: This systematic review and meta-analysis aimed to compare the effectiveness and safety of molnupiravir and sotrovimab in the treatment of patients with coronavirus disease 2019 (COVID-19). Methods: Cochrane Library, Web of Science, PubMed, medRxiv, and Google Scholar were systematically searched to identify relevant evidence up to December 2023. The risk of bias was assessed using the risk of bias in nonrandomized studies of interventions tool. Data were analyzed using Comprehensive Meta-Analysis (CMA). Results: Our search identified and included 13 studies involving 16166 patients. The meta-analysis revealed a significant difference between the molnupiravir and sotrovimab groups in terms of the mortality rate (odds ratio [OR] = 2.07, 95% confidence interval [CI]: 1.16, 3.70). However, no significant difference was observed between the two groups in terms of hospitalization rate (OR = 0.71, 95% CI: 0.47, 1.06), death or hospitalization rate (OR = 1.51, 95% CI: 0.81, 2.83), and intensive care unit admission (OR = 0.59, 95% CI: 0.07, 4.84). In terms of safety, molnupiravir was associated with a higher incidence of adverse events (OR = 1.67, 95% CI: 1.21, 2.30).
Conclusion: The current findings indicate that sotrovimab may be more effective than molnupiravir in reducing the mortality rate in COVID-19 patients. However, no statistical difference was observed between the two treatments for other effectiveness outcomes. The certainty of evidence for these findings was rated as low or moderate. Further research is required to provide a better comparison of these interventions in treating COVID-19 patients.
AUTHOR CONTRIBUTIONS Conceptualization and project administration: Bahman Amani and Behnam Amani. Literature searching: Behnam Amani and Bahman Amani. Data extraction and quality assessment: Bahman Amani and Behnam Amani. Data analysis: Bahman Amani and Behnam Amani. Writing-original draft: Behnam Amani. Writing-review and editing: Bahman Amani and Behnam Amani.
CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest.
SUPPORTING INFORMATION Additional supporting information can be found online in the Supporting Information section at the end of this article.
References
Amani, Amani, Efficacy and safety of sotrovimab in patients with COVID-19: a rapid review and meta-analysis, Rev Med Virol
Amani, Zareei, Amani, Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19, Br J Clin Pharmacol
Behzad, Ali, Niinuma, Butler, Alqahtani, Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2, J Infect Public Health
Benaicha, Khenhrani, Veer, Efficacy of molnupiravir for the treatment of mild or moderate COVID-19 in adults: a meta-analysis, Cureus
Caillard, Thaunat, COVID-19 vaccination in kidney transplant recipients, Nat Rev Nephrol
Calimeri, Lo Giudice, Buda, Role of the 1st booster dose of COVID-19 vaccine in the protection against the infection: a fundamental public health tool, J Prev Med Hyg
Cegolon, Pol, Simonetti, Filon, Luzzati, Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for highrisk COVID-19 patients infected by the omicron variant: hospitalization, mortality, and time until negative swab test in real life, Pharmaceuticals
Cheng, Reyes, Satram, Real-world effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2 Delta and Omicron waves in the USA, Infect Dis Ther
Driouich, Bernadin, Touret, De Lamballerie, Nougairède, Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model, Antiviral Res
Drysdale, Tibble, Patel, Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in Scotland. medRxiv,
doi:10.1101/2023.06.09.23291195Evans, Qi, Adebayo, Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study, J Infect
Fernandes, Inchakalody, Merhi, Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines, Ann Med
Flisiak, Zarębska-Michaluk, Rogalska, Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance, Pharmacol Rep
Gao, Liu, Li, Xu, Zhang et al., Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomised controlled trials, Clin Microbiol Infect
Gleeson, Martin, Thomson, Kidney transplant recipients and omicron: outcomes, effect of vaccines and the efficacy and safety of novel treatments, medRxiv,
doi:10.1101/2022.05.03.22274524Goodwin, Thompson, Hall, Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: the experience of a regional centre in the UK, PLoS One
Huang, Liu, Wu, Tsai, Lai, Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID-19: a systematic review and metaanalysis of randomized control trials, J Med Virol
Hérate, Touret, Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate model, Heliyon
Kamal, Ramadan, Farraj, Bahig, Ezzat, The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review, Saudi Pharm J,
doi:10.1016/j.jsps.2022.03.002Kauer, Totschnig, Karolyi, Zoufaly, Naegeli, Efficacy and tolerability of Sotrovimab Molnupiravir and Nirmatrelvir/Ritonavir for non-hospitalized patients at high risk for COVID-19: a retrospective, single-center analysis,
doi:10.21203/rs.3.rs-2786240.v1Kwok, Tsoi, Leung, Real-world study on effectiveness of molnupiravir and Nirmatrelvir-Ritonavir in unvaccinated patients with chronic respiratory diseases with confirmed SARS-CoV-2 infection managed in out-patient setting, Viruses
Lasagna, Cassaniti, Lilleri, Effectiveness of the available early therapies in reducing severe COVID-19 in nonhospitalized patients with solid tumors on active treatment, Front Med
Lin, Hung, Lai, Wang, Chen, The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: a systematic review and metaanalysis of randomized controlled trials, J Med Virol
Maas, Strizki, Miller, Molnupiravir: mechanism of action, clinical, and translational science, Clin Transl Sci
Malin, Weibel, Gruell, Kreuzberger, Stegemann et al., Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis, J Antimicrob Chemother
Manciulli, Spinicci, Rossetti, Safety and efficacy of outpatient treatments for COVID-19: real-life data from a regionwide cohort of high-risk patients in Tuscany, Italy (the FEDERATE Cohort), Viruses
Martin-Blondel, Marcelin, Soulié, Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2, J Infect
Mazzotta, Lepri, Colavita, Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents, J Med Virol
Minotti, Mengato, Pieri, Early treatments of fragile children with COVID-19-results of CLEVER (Children COVID Early Treatment), a retrospective, observational study, Viruses
Miyashita, Nakamori, Ogata, Clinical efficacy of the neutralizing antibody therapy sotrovimab in patients with SARS-CoV-2 omicron BA.1 and BA.2 subvariant infections, Viruses
Nene, Santodomingo, Balog, Use of sotrovimab in vaccinated versus unvaccinated COVID-19 patients in a resource-limited emergency department during the omicron surge, J Am Coll Emerg Physicians Open
Page, Mckenzie, Bossuyt, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, Int J Surg
Painter, Holman, Bush, Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2, Antimicrob Agents Chemother,
doi:10.1128/aacPatel, Yarwood, Levick, Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England. medRxiv,
doi:10.1101/2022.11.28.22282808Radcliffe, Palacios, Azar, Cohen, Malinis, Realworld experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge, Am J Transplant,
doi:10.1111/ajt.17098Ramos-Rincon, López-Carmona, Cobos-Palacios, Remdesivir in very old patients (≥ 80 years) hospitalized with COVID-19: real world data from the SEMI-COVID-19 registry, J Clin Med
Sterne, Hernán, Reeves, ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, BMJ
Tian, Feng, Chen, Efficacy and safety of molnupiravir treatment for COVID-19: a systematic review and metaanalysis of randomized controlled trials, Int J Antimicro Agents
Tiseo, Barbieri, Galfo, Efficacy and safety of nirmatrelvir/ritonavir, molnupiravir, and remdesivir in a realworld cohort of outpatients with COVID-19 at high risk of progression: the PISA outpatient clinic experience, Infect Dis Ther
Touret, Baronti, Bouzidi, De Lamballerie, In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate, Sci Rep
Twohig, Nyberg, Zaidi, Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study, Lancet Infect Dis
Uraki, Kiso, Imai, Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters, Nat Microbiol
Vito, Colpani, Poliseno, What is the efficacy of sotrovimab in reducing disease progression and death in people with COVID-19 during the omicron era? Answers from a real-life study, Viruses
Wen, Chen, Tang, Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis, Ann Med
Wong, Au, Lau, Lau, Cowling et al., Realworld effectiveness of early molnupiravir or nirmatrelvirritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study, Lancet Infect Dis
Zheng, Campbell, Carr, Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients on kidney replacement therapy: observational cohort study using the OpenSAFELY-UKRR linked platform and SRR database, medRxiv,
doi:10.1101/2022.12.02.22283049Zheng, Green, Tazare, Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform, BMJ,
doi:10.1136/bmj-2022-071932
